Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed the day trading at $45.14 down -5.35% from the previous closing price of $47.69. In other words, the price has decreased by -$5.35 from its previous closing price. On the day, 1.95 million shares were traded. CRNX stock price reached its highest trading level at $47.975 during the session, while it also had its lowest trading level at $43.04.
Ratios:
For a better understanding of CRNX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Pizzuti Dana sold 5,000 shares for $45.02 per share. The transaction valued at 225,100 led to the insider holds 66,837 shares of the business.
DANA PIZZUTI bought 5,000 shares of CRNX for $227,800 on Dec 01 ’25. On Nov 03 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 5,000 shares for $42.66 each. As a result, the insider received 213,312 and left with 66,270 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 4283417600 and an Enterprise Value of 3240270592. For the stock, the TTM Price-to-Sale (P/S) ratio is 2799.62 while its Price-to-Book (P/B) ratio in mrq is 3.98. Its current Enterprise Value per Revenue stands at 2110.926 whereas that against EBITDA is -6.834.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.19, which has changed by -0.1102612 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $55.47, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is 2.01%, while the 200-Day Moving Average is calculated to be 28.10%.
Shares Statistics:
Over the past 3-months, CRNX traded about 1.59M shares per day on average, while over the past 10 days, CRNX traded about 956030 shares per day. A total of 94.55M shares are outstanding, with a floating share count of 88.18M. Insiders hold about 7.07% of the company’s shares, while institutions hold 110.05% stake in the company. Shares short for CRNX as of 1764288000 were 13873038 with a Short Ratio of 8.73, compared to 1761868800 on 13537482. Therefore, it implies a Short% of Shares Outstanding of 13873038 and a Short% of Float of 16.610001.
Earnings Estimates
The company has 11.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$1.41, with high estimates of -$1.19 and low estimates of -$1.7.
Analysts are recommending an EPS of between -$4.07 and -$5.19 for the fiscal current year, implying an average EPS of -$4.95. EPS for the following year is -$5.22, with 12.0 analysts recommending between -$3.94 and -$7.04.
Revenue Estimates
For the next quarter, 12 analysts are estimating revenue of $6.58M. There is a high estimate of $11.1M for the next quarter, whereas the lowest estimate is $4.6M.
A total of 13 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.54M, while the lowest revenue estimate was $2.5M, resulting in an average revenue estimate of $5.02M. In the same quarter a year ago, actual revenue was $1.04MBased on 13 analysts’ estimates, the company’s revenue will be $54.84M in the next fiscal year. The high estimate is $112.07M and the low estimate is $20.68M.
